UTMD — Utah Medical Products Income Statement
0.000.00%
Last trade - 00:00
- $246.13m
- $153.27m
- $50.22m
- 93
- 57
- 29
- 61
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 46.9 | 42.2 | 49.1 | 52.3 | 50.2 |
Cost of Revenue | |||||
Gross Profit | 29.5 | 25.5 | 30.9 | 32.2 | 30 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 29.3 | 28.5 | 30.2 | 32.5 | 33.4 |
Operating Profit | 17.6 | 13.7 | 18.9 | 19.8 | 16.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 17.9 | 13.8 | 19.1 | 20.7 | 20.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 14.5 | 11.1 | 14.8 | 16.5 | 16.6 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 14.7 | 10.8 | 14.8 | 16.5 | 16.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 14.7 | 10.8 | 14.8 | 16.5 | 16.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.87 | 3.01 | 4.05 | 4.67 | 4.95 |
Dividends per Share | |||||
Special Dividends per Share |